Treatment of Cardiovascular Diseases - Taiwan

In Taiwan, the Treatment of Cardiovascular Diseases market is expected to witness significant revenue growth.
By 2024, the projected revenue is estimated to reach US$2.39bn.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of 4.78%, resulting in a market volume of US$3.01bn by 2029.
When compared globally, United States is projected to generate the highest revenue in the Treatment of Cardiovascular Diseases market.
In 2024, the revenue United States is expected to reach a staggering US$136.00bn.
Taiwan has witnessed a surge in the adoption of innovative cardiac treatment methods, positioning it as a frontrunner in the field of cardiovascular disease management.

Definition:
Treatments of Cardiovascular Diseases refers to the treatment of patients with diseases or disorders that affect the circulatory system, including coronary artery disease, heart disease, and stroke. During their stay in the hospital, patients are provided with necessary surgical procedures, medication management, and any medical intervention that is needed to manage their symptoms, prevent complications, and further progression of the disease, thus improving their overall health and well-being.

Additional information:
The Treatments of Cardiovascular Diseases market comprises revenues and average revenue per capita. Market values represent revenues paid to hospitals by the respective healthcare payers (including VAT, if applicable). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.

Diagnostic testing
Medication received during inpatient treatments
Continuous monitoring, such as tracking heart rate or blood pressure
Interventional procedures, such as angioplasty or stenting

Long-term rehabilitative care
Home-based rehabilitative care

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Heart disease is the leading cause of death in the United States, accounting for around 21 percent of all deaths in 2022. Cardiovascular disease is a general term that is used to refer to many different conditions that affect the heart, including coronary heart disease, the most common type of heart disease, as well as heart failure, rheumatic heart disease, myocardial infarction (heart attack), and stroke. In addition to the loss of life, cardiovascular diseases also have a significant economic burden and although many cases are preventable by avoiding known risk factors, the risk of these diseases increases greatly with age. From 2019 to 2022, around 15 percent of those aged 65 years and older in the United States had been diagnosed with heart disease.